XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Stock Information for XTL Biopharmaceuticals Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XTL Biopharmaceuticals Ltd.

XTL Update on Recent Developments
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL To Aquire The Social Proxy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.